Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monoprost vs Lumigan in Glaucoma/OHT with Intolerance
NCT02017327Phase 4Completed
- Sponsor
- Laboratoires Théa
- Start
- Dec 2013
- Primary completion
- Jul 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of latanoprost in primary open-angle glaucoma (POAG) and ocular hypertension (3 arms), sponsored by Laboratoires Théa. Primary endpoint: Assessment of Conjunctival Hyperaemia in the Worse Eye at Day 84. Started Dec 2013; status: completed.
02
Drugs
latanoprost
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT02017327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017327.